Trial enrolling up to 30,000 adults aged 18 years or over to assess safety, efficacy and immunogenicity of AZD1222 for the prevention of COVID-19 AZD1222 supported by safety and immunogenicity across all adult age groups Vaccitech Ltd, a clinical-stage...
Year: 2020
Vaccitech receives government grant for COVID-19 vaccine research
Oxford, UK - Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces today that it has received a non-dilutive Government grant to support research with its next-generation...
Vacancy: Senior Scientist – Process Development
Due to exciting expansion across the company, with offices in the UK (headquarters), USA, Italy and Australia, Vaccitech is now recruiting for a Senior Scientist - Process Development, which is an office and laboratory-based role in the UK. Please see the role...
Clinical trial data shows Oxford University’s COVID-19 vaccine produces strong immune response
Vaccitech Ltd, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces that Oxford University’s Jenner Institute and Oxford Vaccine Group have taken the next step towards the discovery of a...
First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients
Oxford, UK – Vaccitech Ltd, a clinical stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces today that it has dosed the first person in a Phase 1 clinical study to investigate the safety and...
Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
Vaccitech Ltd and the University of Oxford today announce an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being...
Oxford COVID-19 vaccine begins human trial stage
Oxford, UK - Vaccitech announces today that its scientific founders at the Jenner Institute, University of Oxford, have begun testing a COVID-19 vaccine in human volunteers. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half...
Vaccitech to Present at Solebury Trout Virtual Investor Conference
Oxford, UK – 30th March 2020 Vaccitech Ltd, a clinical stage biopharmaceutical company developing immunotherapies to treat infectious diseases and cancer, announced today that its Chief Executive Officer, Bill Enright, will present an update on the Company’s progress...
Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
Oxford, UK – Vaccitech Limited and the University of Oxford today announce initial efficacy and safety data for ADVANCE, a Phase 2a study testing VTP-800, an immunotherapeutic product candidate in patients with metastatic castration resistant prostate cancer (mCRPC)....
Vacancy: Clinical Programme Lead
To assist with the coordination and oversight of cross-functional activities to support the Vaccitech portfolio of research and development programmes. All activities carried out within allocated time, and agreed costs in accordance with quality requirements,...